Defibrinated bovine plasma inhibits retroviral transcription by blocking p52 activation of the NKκB element in the long terminal repeat

Canadian Journal of Veterinary Research

Volumn 71, Issue 2, 2007, Pages 119-128

  van den Heuvel, Marianne J ^a   Copeland, Karen F ^b   Cates, Elizabeth C ^c   Jefferson, Barbara J ^d   Jacobs, Robert M ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONOMYCIN; PHORBOL ESTER; PROTEIN P52;

ARTICLE; BOVIDS; BOVINE LEUKEMIA VIRUS; CELL CULTURE; CELL LINE; CELL NUCLEUS; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME SYNTHESIS; FELINE IMMUNODEFICIENCY VIRUS; FELINE LEUKEMIA VIRUS; GEL MOBILITY SHIFT ASSAY; GENE CONSTRUCT; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; MONONUCLEAR CELL; NONHUMAN; PLASMA; PROMOTER REGION; PROTEIN FAMILY; PROTEIN INDUCTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REPORTER GENE; RETROVIRUS; TRANSCRIPTION INITIATION SITE; UPREGULATION; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS LATENCY; VIRUS TRANSCRIPTION;

ANIMALS; ANTIGENS, NEOPLASM; CATTLE; CELLS, CULTURED; CHLORAMPHENICOL O-ACETYLTRANSFERASE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; LEUKEMIA VIRUS, BOVINE; NF-KAPPA B; PLASMA; TERMINAL REPEAT SEQUENCES; TRANSCRIPTION, GENETIC; TRANSFECTION; VIRUS LATENCY;

BOS; BOVINAE; BOVINE IMMUNODEFICIENCY VIRUS; BOVINE LEUKEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; FELINE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34248377022     PISSN: 08309000     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Burny A, Cleuter Y, Kettmann R, et al. Bovine leukemia: facts and hypotheses derived from the study of an infectious cancer. Adv Vet Sci Comp 1988;32:149-170.
2. Derse D. Bovine leukemia virus transcription is controlled by a virus-encoded trans-acting factor and by cis-acting response elements. J Virol 1987;61:2462-2471.
3. Rice NR, Simek SL, Dubois GC, Showalter SD, Gilden RV, Stephens RM. Expression of the bovine leukemia virus X region in virus-infected cells. J Virol 1987;61:1577-1585.
4. Adam E, Kerkhofs P, Mammerickx M, et al. Involvement of the cyclic AMP-responsive element binding protein in bovine leukemia virus expression in vivo. J Virol 1994;68:5845-5853.
5. Adam E, Kerkhofs P, Mammerickx M, Burny A, Kettman R, Willems L. The CREB, ATF-1, and ATF-2 transcription factors from bovine leukemia virus-infected B lymphocytes activate viral expression. J Virol 1996;70:1990-1999.
6. Calomme C, Nguyen TL, de Launoit Y, et al. Upstream stimulatory factors binding to an E box motif in the R region of the bovine leukemia virus long terminal repeat stimulates viral gene expression. J Biol Chem 2002;277:8775-8779.
7. Derse D, Martarano L. Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity. J Virol 1990; 64:401405.
8. Katoh I, Yoshinaka Y, Ikawa Y. Bovine leukemia virus transactivator p38tax activates heterologous promoters with a common sequence known as a cAMP-responsive element or the binding site of a cellular transcription factor ATF. EMBO J 1989;8: 497-503.
9. Willems L, Grimonpont C, Heremans H, et al. Mutations in the bovine leukemia virus Tax protein can abrogate the long terminal repeat-directed transactivating activity without concomitant loss of transforming potential. Proc Natl Acad Sci U S A 1992;89:3957-3961.
10. Brooks PA, Nyborg JK, Cockerell GL. Identification of an NF-kappa B binding site in the bovine leukemia virus promoter. J Virol 1995;69:6005-6009.
11. Niermann GL, Buehring GC. Hormone regulation of bovine leukemia virus via the long terminal repeat. Virology 1997;239: 249-258.
12. Xiao J, Buehring GC. In vivo protein binding and functional analysis of cis-acting elements in the U3 region of the bovine leukemia virus long terminal repeat. J Virol 1998;72:5994-6003.
13. Gupta P, Kashmiri SV, Ferrer JF. Transcriptional control of the bovine leukemia virus genome: role and characterization of a non-immunoglobulin plasma protein from bovine leukemia virus-infected cattle. J Virol 1984;50:267-270.
14. Kettmann R, Deschamps J, Cleuter Y, Couez D, Burny A, Marbaix G. Leukemogenesis by bovine leukemia virus: proviral DNA integration and lack of RNA expression of viral long terminal repeat and 3' proximate cellular sequences. Proc Natl Acad Sci U S A 1982;79:2465-2469.
15. Jensen WA, Rovnak J, Cockerell GL. In vivo transcription of the bovine leukemia virus tax/rex region in normal and neoplastic lymphocytes of cattle and sheep. J Virol 1991;65: 2484-2490.
16. Stone DM, Norton LK, Davis WC. Spontaneously proliferating lymphocytes from bovine leukaemia virus-infected, lymphocytotic cattle are not the virus-expressing lymphocytes, as these cells are delayed in G(0)/G(1) of the cell cycle and are spared from apoptosis. J Gen Virol 2000;81:971-981.
17. Djilali S, Parodi AL, Levy D. Bovine leukemia virus replicates in sheep B lymphocytes under a T cell released factor. Eur J Cancer Clin Oncol 1987;23:81-85.
18. Cornil I, Delon P, Parodi AL, Levy D. T-B cell cooperation for bovine leukemia virus expression in ovine lymphocytes. Leukemia 1988;2:313-317.
19. Lagarias DM, Radke K. Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections. J Virol 1989;63:2099-2107.
20. Bondzio A, Abraham-Podgornik A, Blankenstein P, Risse S. Involvement of intracellular Ca2+ in the regulation of bovine leukemia virus expression. Biol Chem 2001;382:407-416.
21. Zandomeni RO, Carrera-Zandomeni M, Esteban E, Donawick W, Ferrer JF. Induction and inhibition of bovine leukaemia virus expression in naturally infected cells. J Gen Virol 1992;73: 1915-1924.
22. Taylor JA, Jacobs RM. Effects of plasma and serum on the in vitro expression of bovine leukemia virus. Lab Invest 1993;69: 340-346.
23. Zandomeni RO, Esteban E, Carrera-Zandomeni M, Ferrer JF. Host soluble factors with blocking and stimulating activity on the expression of the bovine leukemia virus. J Infect Dis 1994;170:787-794.
24. van den Heuvel M, Portetelle D, Jefferson B, Jacobs RM. Adaptation of a sandwich enzyme-linked immunosorbent assay to determine the concentration of bovine leukemia virus p24 and optimal conditions for p24 expression in short-term cultures of peripheral blood mononuclear cells. J Virol Methods 2003;111:61-67.
25. Copeland KF, Haaksma AG, Derse D, Goudsmit J, Heeney JL. Cytochemical analysis of human T cell leukaemia virus I LTR-regulated beta-galactosidase gene expression using a novel integrated cell system. J Virol Methods 1993;45:161-167.
26. Derse D, Caradonna SJ, Casey JW. Bovine leukemia virus long terminal repeat: a cell type-specific promoter. Science 1985;227:317-320.
27. Peterlin BM, Luciw PA, Barr PJ, Walker MD. Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus. Proc Natl Acad Sci U S A 1986;83:9734-9738.
28. Sparger EE, Shackled BL, Renshaw-Gegg L, et al. Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 1992;187:165-177.
29. Feghali CA, Bost KL, Boulware DW, Levy LS. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994;17:309-318.
30. Rosen CA, Sodroski JG, Haseltine WA. Location of cis-acting regulatory sequences in the human T-cell leukemia virus type I long terminal repeat. Proc Natl Acad Sci U S A 1985;82:6502-6516.
31. Carpenter S, Nadin-Davis SA, Wannemuehler Y, Roth JA. Identification of transactivation-response sequences in the long terminal repeat of bovine immunodeficiency-like virus. J Virol 1993;67:4399-4403.
32. Brooks PA, Cockerell GL, Nyborg JK. Activation of BLV transcription by NF-kappa B and tax. Virology 1998;243:94-98.
33. DiDonato JA, Mercurio F, Karin M. Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B. Mol Cell Biol 1995;15:1302-1311.
34. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995;14:2876-2883.
35. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109 Suppl:S81-S96.
36. Cornil I, Levy D. In vivo inhibition of bovine leukemia virus (BLV) expression. Leukemia 1989;3:159-161.
37. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-256.
38. van den Heuvel MJ, Jefferson BJ, Jacobs RM. Isolation of a bovine plasma fibronectin-containing complex which inhibits the expression of bovine leukemia virus p24. J Virol 2005;79:8164-8170.
39. Pallis M, Robins RA, Powell RJ. Peripheral blood lymphocyte binding to a soluble FITC-fibronectin conjugate. Cytometry 1997;28:157-164.
40. van den Heuvel M, Jefferson B, Jacobs RM. Purified bovine plasma blocking factor decreases Bovine leukemia virus p24 expression while increasing protein synthesis and transcriptional activity of peripheral blood mononuclear cells in short-term culture. Can J Vet Res 2005;69:186-192.